Ionis Pharmaceuticals lowered its 2026 Tryngolza sales outlook to about $50 million, while companywide results for the third quarter exceeded expectations for revenue and earnings.
The company set a 2026 sales target of about $50 million for Tryngolza. Its earlier outlook ranged from $100 million to $110 million.
Tryngolza is used to treat severe hypertriglyceridemia. For the quarter ended Sept. 30, Ionis reported $243 million in revenue and a GAAP loss of $0.66 per share.
Those revenue and loss figures cover Ionis overall for the quarter; the $50 million outlook applies to Tryngolza sales for the full year.
